Igovomab

CHEMBL2109036 Phase 4 承認済み Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This radiolabeled antibody fragment targets a protein called CA-125, which is often elevated in ovarian cancer, and was investigated for imaging purposes to detect and monitor ovarian tumors. It belongs to a class of diagnostic agents designed to locate cancer cells in the body.

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This radiolabeled antibody fragment targets a protein called CA-125, which is often elevated in ovarian cancer, and was investigated for imaging purposes to detect and monitor ovarian tumors. It belongs to a class of diagnostic agents designed to locate cancer cells in the body.

Yes, Igovomab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109036. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.